Atomo Diagnostics Ltd. · ASX:AT1
Atomo Diagnostics — FY2021 Earnings Presentation
21 slides from Atomo Diagnostics's earnings presentation, Aug 27, 2021
Slide 1: FY21 Results Presentation
This announcement was authorised by John Kelly, Managing Director Atomo Diagnostics Limited 701 – 703 Parramatta Road Leichhardt NSW 2040 Australia FY21 Results Presentation 27 August 2021 ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on the opportunity outlined in this presentation and no representation or warranty is made in information available as at the date of this presentation. The information in this presentation respect of such in
Slide 3: Introduction
INTRODUCTION Atomo Diagnostics Limited (ASX: AT1) is an innovative medical device company supplying unique, integrated rapid diagnostic test (RDT) devices to the global diagnostic market Headquartered in Australia with global operations, Atomo develops, manufactures and supplies innovative, patented
Slide 4: Key FY21 Highlights
KEY FY21 HIGHLIGHTS • Atomo COVID-19 rapid Antibody and Antigen tests – Added by the TGA to the ARTG* in H1 FY21 for supply in Australia. Circa. 50k, primarily antibody test units sold in H2 FY21. Antigen test demand commenced in Q4, stepping up very significantly in Q1 FY22 • Access Bio Inc. (USA)
Slide 5: FY21 Deliverables – Progress on Track
FY21 DELIVERABLES – PROGRESS ON TRACK COVID-19 DELIVERED ✓ North American deal with US Co. Access Bio Q1 FY21 ✓ AtomoRapid COVID-19 professional use test TGA Approval (Australia) Q1 FY21 ✓ AtomoRapid COVID-19 professional use test to be launched in Australia Q2 FY21 ✓ Commence supply of Galileo to A
Slide 6: COVID-19 Rapid Testing Is Here to Stay
C O V I D - 1 9 R A P I D T E S T I N G I S H E R E T O S TAY COVID-19 COVID-19 Business Performance (FY21) • Demand for Atomo platforms for use in COVID-19 • COVID-19 Sales Revenue - $3.68m antibody testing in FY21 with 1.1m units sold to NG • COVID-19 OEM Units Sold – 1.1m and Access Bio for Europ
Slide 7: HIV Testing – Global Health Underpins Growth
H I V T E S T I N G – G L O B A L H E A LT H U N D E R P I N S G R O W T H HIV Self-Test HIV Business Performance (FY21) • Atomo’s HIV self-test is the only HIV self- • HIV Sales Revenue - $1.08m test approved in Australia (TGA). Also approved in Europe (CE Mark) and • HIV Units Sold - 268k prequali
Slide 8: Strengthening OEM Interest Post-Pandemic
S T R E N G T H E N I N G O E M I N T E R E S T P O S T - PA N D E M I C Strategic Partnership Journey OEM Business Performance (FY21) • Initially Atomo entered into OEM supply • OEM Sales Revenue – $1.98m agreements with a number of early adopters that have proven the utility, • OEM Units Sold – 1.
Slide 9: FY21 – Profit and Loss
FY21 – PROFIT AND LOSS • Revenue increased by 25% to $6.7m, driven by: • strong momentum in customer demand for the Group’s COVID-19 point of care antibody & antigen testing devices • As higher volume OEM and HIV business contributed more to the overall product mix during FY21 when compared to FY20
Slide 10: FY21 – Balance Sheet
FY21 –BALANCE SHEET • Cash balance of $17.95 million as at 30 June 2021 • Trade receivables & payables continues to remain within expectations • Inventories continue to ramp up to supply into OEM, HIV and COVID-19 OEM and Finished Product channels • Continued strong investment in production capacity
Slide 11: FY21 – Cashflow Activities
FY21 – CASHFLOW ACTIVITIES • Cash receipts of $8.1m for the year underpin continued investment in growth • Cash outflows predominantly consisting of: • revenue generating investments; payments for inventory of $5.5m to meet demand from customers in OEM, COVID-19 and HIV • expansion of Atomo faciliti
Slide 12: Atomo's Story
AT O M O ’ S S T O R Y Atomo’s founder, John Kelly, came into diagnostics with a track record of radically transforming the user experience and health outcomes in the medical device field. By arming consumers with simple to use, fast, accurate diagnoses and a seamless pathway to treatment, Atomo emp
Slide 13: Standard Rapid Testing: Off Patent & Complex
S TA N D A R D R A P I D T E S T I N G : O F F PAT E N T & C O M P L E X Traditional ‘bits in a box’ Lateral Flow kits • Rapid Lateral flow based technology was commercialised more than 30 years ago and is now broadly off patent • This has resulted in low barriers to entry with many players entering
Slide 14: Atomo's Solution – Integration & Elegance
AT O M O ’ S S O L U T I O N S – I N T E G R AT I O N & E L E G A N C E For Atomo, a good lateral assay test is only the starting point to a good diagnostic test… if it can’t be easily used in real-life settings user-driven error rates undermine the test itself Pascal Test – supports professional an
Slide 15: Regulatory Approvals
R E G U L AT O R Y A P P R O VA L S Australian TGA • The Atomo COVID-19 Antigen Test is approved by the TGA (ARTG 346587). • The AtomoRapid Covid-19 (IgG/IgM) Rapid Antibody Test is approved by the TGA (ARTG 341411). • The Atomo HIV Self Test is the only approved HIV self test approved by the TGA (A
Slide 16: Robust Globally Protected IP Position
R O B U S T G L O B A L LY P R O T E C T E D I P P O S I T I O N Family 1: Diagnostic System PCT/AU2011/000315 Relates to an integrated test system incorporating lancet, test, and internal buffer reservoir. The system is such that buffer is brought into contact with the test component only after the
Slide 17: Atomo Operations
AT O M O O P E R AT I O N S ( E N D O F 2 0 2 1 ) PRODUCT CAPACITY: Pascal (OEM) – 400K p.m. Galileo (OEM) – 1.0M p.m. HIV (using Galileo) – 350K p.m Harrisburg, PA: Blister M/c 1 SHENZHEN: 600K p.m. Galileo - 1.0M p.m. Pascal – 400K p.m.. SYDNEY: Blister M/c 2 - 750k p.m.* Cape Town: HIV S.T. Finis
Slide 18: Atomo – Positive Impact in the Community
AT O M O – P O S I T I V E I M PA C T I N T H E C O M M U N I T Y “We are proud of our initiative to introduce rapid antigen testing in July 2021. As a result of using Atomo Rapid testing, which the “Sadly, stigma and embarrassment still Government is soon introducing into high-risk prevents many pe
Slide 19: FY22 - A New Rapid Test Landscape
FY22 - A NEW RAPID TEST LANDSCAPE • The COVID-19 pandemic has fundamentally changed the diagnostics landscape, as well as reinforcing the critical need for accurate and easy to use point of care and home-based diagnostics as part of a broader healthcare offering • With a range of new OTC and home te
Slide 20: Priorities for FY22
PRIORITIES FOR FY22* Continued expansion of strategic commercialisation partnerships across key global markets, including seeking US market entry partnership Continue to expand COVID-19 revenues with a core focus on the Australian market and expanding HIV sales in existing territories and securing c
Slide 21: John Kelly, Managing Director
John Kelly Managing Director john.kelly@atomodiagnostics.com +61 401 922 279 atomodiagnostics.com